H1 performance was in line with expectations. Looking out, the early completion of recruitment into the PeproStat Haemostatix trial means the read out is expected in Q4 2017, substantially ahead of schedule. The valuation range remains unchanged at 232p - 397p and the business remains on track to match expectations of significant growth.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Outlook focused on PeproStat data soon
- Published:
18 Sep 2017 -
Author:
Elizabeth Klein -
Pages:
3
H1 performance was in line with expectations. Looking out, the early completion of recruitment into the PeproStat Haemostatix trial means the read out is expected in Q4 2017, substantially ahead of schedule. The valuation range remains unchanged at 232p - 397p and the business remains on track to match expectations of significant growth.